Opicapone Disease Interactions

The use of opicapone is contraindicated in patients with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

Opicapone may cause impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating, and compulsive eating. Patients with a major psychotic disorder should ordinarily not be treated with this drug because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.

The pharmacokinetics of opicapone have not been studied in patients with end stage renal disease. Caution is advised.

Opicapone may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down. Caution is advised in patients with hypotension.

The mean overall plasma exposure (AUC) of opicapone increased by 84% in patients with moderate (Child-Pugh Class B) liver dysfunction. A dosage adjustment is required on these patients. The pharmacokinetics of this drug have not been studied in patients with severe liver dysfunction (Child-Pugh: C). Caution is advised.

Opicapone formulations contain lactose. Caution is advised if used in patients with lactose intolerance.